<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="7469" end="7473" sStart="7344" offset="125" sid="r1.rule.v.0016" wn="2147483647" wnkey="null" text="Persistent microalbuminuria should be confirmed on two or three subsequent readings within a six-month period to rule out false-positive results." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="7469" end="7473" sStart="null" offset="125" sid="r1.rule.v.0016" wn="2147483647" wnkey="null" text="Persistent microalbuminuria should be confirmed on two or three subsequent readings within a six-month period to rule out false-positive results." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="7469" end="7473" sStart="null" offset="125" sid="r1.rule.v.0016" wn="2147483647" wnkey="null" text="Persistent microalbuminuria should be confirmed on two or three subsequent readings within a six-month period to rule out false-positive results." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="121" end="129" sStart="null" offset="69" sid="r11.refer.v.0117" wn="4" wnkey="refer%2:38:00::" text="A 31-year-old white male with no significant past medical history is referred by his workplace to a primary care physician for an elevated blood pressure (BP)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="4340" end="4350" sStart="null" offset="8" sid="r11.recommend.v.0786" wn="1" wnkey="recommend%2:32:01::" text="The ADA recommends glycemic and other CVD risk factor goals (see Table 2), in addition to foot evaluation and screening for nephropathy and retinopathy, for all adults with diabetes [4]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="11375" end="11381" sStart="null" offset="67" sid="r9.normal.j.0577" wn="1" wnkey="normal%3:00:01::" text="The remainder of his examination is unchanged, including normal fundoscopy." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="11546" end="11552" sStart="null" offset="47" sid="r9.normal.j.0065" wn="3" wnkey="normal%3:00:03::" text="His creatinine and liver enzymes are normal." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="11546" end="11552" sStart="null" offset="47" sid="r9.normal.j.0065" wn="3" wnkey="normal%3:00:03::" text="His creatinine and liver enzymes are normal." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="3868" end="3874" sStart="null" offset="194" sid="r9.normal.j.0524" wn="1" wnkey="normal%3:00:01::" text="His additional investigations are as follows: fasting glucose, 215 mg/dl; hemoglobin A1c (HbA 1c ), 8.6%; and urine albumin-to-creatinine ratio, 2.0 mg/mmol (normal is &lt;2." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="11546" end="11552" sStart="null" offset="47" sid="r9.normal.j.0065" wn="1" wnkey="normal%3:00:01::" text="His creatinine and liver enzymes are normal." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="11546" end="11552" sStart="null" offset="47" sid="r9.normal.j.0065" wn="2" wnkey="normal%3:00:02::" text="His creatinine and liver enzymes are normal." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="2438" end="2442" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" text="He has nocturia and has &lt;b&gt;lost&lt;/b&gt; 5 lb in the last week." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="1784" end="1788" sStart="null" offset="139" sid="r10.high.j.0668" wn="1" wnkey="high%3:00:02::" text="It may be timely to address the prevention of diabetes in patients with metabolic syndrome since these patients are at high risk for development of type 2 diabetes." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="10425" end="10433" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="It is important to continue emphasis on dietary, &lt;b&gt;exercise&lt;/b&gt;, and lifestyle modifications in addition to pharmacotherapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="10425" end="10433" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="It is important to continue emphasis on dietary, &lt;b&gt;exercise&lt;/b&gt;, and lifestyle modifications in addition to pharmacotherapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="2036" end="2044" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="The patient is started on an &lt;b&gt;exercise&lt;/b&gt; and weight loss program, sent for nutritional counseling, and scheduled for a return clinic appointment for three months later." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="1498" end="1506" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="Intensive lifestyle modifications such as &lt;b&gt;exercise&lt;/b&gt; and weight loss should be made to improve cholesterol, blood pressure, and other cardiovascular disease (CVD) risk factors [2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="2036" end="2044" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="The patient is started on an &lt;b&gt;exercise&lt;/b&gt; and weight loss program, sent for nutritional counseling, and scheduled for a return clinic appointment for three months later." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="10425" end="10433" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="It is important to continue emphasis on dietary, &lt;b&gt;exercise&lt;/b&gt;, and lifestyle modifications in addition to pharmacotherapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="2036" end="2044" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="The patient is started on an &lt;b&gt;exercise&lt;/b&gt; and weight loss program, sent for nutritional counseling, and scheduled for a return clinic appointment for three months later." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="1498" end="1506" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="Intensive lifestyle modifications such as &lt;b&gt;exercise&lt;/b&gt; and weight loss should be made to improve cholesterol, blood pressure, and other cardiovascular disease (CVD) risk factors [2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="2036" end="2044" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="The patient is started on an &lt;b&gt;exercise&lt;/b&gt; and weight loss program, sent for nutritional counseling, and scheduled for a return clinic appointment for three months later." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020040.anc" start="10425" end="10433" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="It is important to continue emphasis on dietary, &lt;b&gt;exercise&lt;/b&gt;, and lifestyle modifications in addition to pharmacotherapy." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="9560" end="9567" sStart="null" offset="45" sid="r10.control.n.0709" wn="2" wnkey="control%1:24:00::" text="In addition, continued strict BP control is as effective as tight glycemic control in preventing macrovasular disease in diabetic patients and slowing the progression of diabetic nephropathy and retinopathy [12]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="14825" end="14837" sStart="null" offset="155" sid="r11.combination.n.0508" wn="1" wnkey="combination%1:14:00::" text="Intensive therapy in patients with type 2 diabetes results in a decreased risk of microvascular complications; therefore, it is appropriate to use combinations of medications in patients with suboptimal glycemia [21]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="16934" end="16946" sStart="null" offset="31" sid="r11.combination.n.0302" wn="1" wnkey="combination%1:14:00::" text="Insulin and insulin-sensitizer combinations significantly improve hyperglycemia; however, there is an increased incidence of heart failure reported with this combination, prompting close monitoring of patients for signs and symptoms of heart failure [27]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="17077" end="17088" sStart="null" offset="174" sid="r11.combination.n.0079" wn="1" wnkey="combination%1:14:00::" text="Insulin and insulin-sensitizer combinations significantly improve hyperglycemia; however, there is an increased incidence of heart failure reported with this combination, prompting close monitoring of patients for signs and symptoms of heart failure [27]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="15743" end="15755" sStart="null" offset="32" sid="r11.combination.n.0525" wn="1" wnkey="combination%1:14:00::" text="Insulin is used in a variety of combinations and is individualized to patient lifestyle." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="17077" end="17088" sStart="null" offset="174" sid="r11.combination.n.0079" wn="1" wnkey="combination%1:14:00::" text="Insulin and insulin-sensitizer combinations significantly improve hyperglycemia; however, there is an increased incidence of heart failure reported with this combination, prompting close monitoring of patients for signs and symptoms of heart failure [27]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020040.anc" start="4646" end="4653" sStart="null" offset="23" sid="r9.appear.v.0415" wn="4" wnkey="appear%2:39:01::" text="Therapy with metformin appears to decrease the risk of diabetes-related endpoints, including a reduction in cardiovascular events independent of glycemic control." />
  </sentences>
</list>